DEA

Description: 
This handout discusses how a prescribing physician may prepare for a visit from the DEA. Such visits are required by law for physicians prescribing buprenorphine, and involve things such as prescription and dispensing records, and adherence to prescribing limits on number of patients.
Source: 
PCSS
field_vote: 
Physician stage in practice: 
Commonly Used Forms: 
Description: 
This is a list of each state's prescription monitoring program contact information.
Source: 
National Association of State Controlled Substances Authorities (NASCSA)
field_vote: 
Description: 
These FAQs address common questions regarding prescription drug monitoring programs.
Source: 
Drug Enforcement Agency (DEA)
field_vote: 
Description: 
This is the NASPER website which includes various information on the $60 million dollar 2005 grant to help states start or improve state-run prescription monitoring programs (PMPs).
Source: 
American Society of Interventional Pain Physicians
field_vote: 
Physician stage in practice: 
Description: 
This 2006 document explains the Drug Enforcement Agency's (DEA) role in regulation of controlled substances and the physician's legal responsibility to prescribe controlled substances for legitimate medical purposes.
Source: 
Drug Enforcement Agency (DEA)
field_vote: 
Description: 
This survey of 375 physicians found that confidence addressing drug problems was positively associated with having a buprenorphine waiver.
Source: 
Journal of General Internal Medicine, 2007
field_vote: 
Description: 
This is the full text of Title 21, Chapter 13 of the US Code, which deals with drug abuse prevention and control.
Source: 
Drug Enforcement Administration (DEA)
field_vote: 
Description: 
This page provides links to the full text, summary, and physician waiver requirements under DATA 2000.
Source: 
Substance Abuse and Mental Health Services Administration (SAMHSA)
field_vote: 
Physician stage in practice: 
Description: 
This form dated 2006 was for physicians to notify the DEA (through the Substance Abuse and Mental Health Services Administration) of their intent to use Schedule III, IV, or V drugs for treatment of opioid dependent patients. See SAMHSA's Buprenorphine Waiver Management page for the latest information on what form to use for this purpose.
Source: 
The National Alliance of Advocates for Buprenorphine Treatment (NAABT)
field_vote: 
Resource Type: 
Commonly Used Forms: 
Physician stage in practice: 
Description: 
This report by SAMHSA addresses the issues of buprenorphine diversion and abuse of which have developed in recent years. The report gives a summary of the findings on diversion and abuse and recommendations for the future.
Source: 
Substance Abuse and Mental Health Services Administration (SAMHSA)
field_vote: 
Physician stage in practice: 
Resource Type: 

Pages

Subscribe to DEA